Preskoči na sadržaj
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Sva polja
Naslov
Autor
Tema
Signatura
ISBN/ISSN
Oznaka
Pronađi
Napredno
Ranibizumab versus Bevacizuma...
Citiraj ovo
Pošalji tekstualnu poruku
Pošalji ovo e-mailom
Ispiši
Izvezi zapis
Izvezi u RefWorks
Izvezi u EndNoteWeb
Izvezi u EndNote
Stalna poveznica
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Bibliografski detalji
Glavni autori:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Format:
Journal article
Izdano:
2012
Primjerci
Opis
Slični predmeti
Prikaz za djelatnike knjižnice
Slični predmeti
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
od: Chakravarthy, U, i dr.
Izdano: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
od: Chakravarthy, U, i dr.
Izdano: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
od: Dakin, H, i dr.
Izdano: (2014)
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
od: Wen-Jie Wang, i dr.
Izdano: (2015-02-01)
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
od: Zhe-Li Liu, i dr.
Izdano: (2013-04-01)